Clinical trialNCT04301076RecruitingPhase 1Interventional

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

SponsorNational Cancer Institute (NCI)Enrollment30Acute Adult T-Cell Leukemia/LymphomaAdult T-Cell Leukemia/LymphomaChronic Adult T-Cell Leukemia/LymphomaHTLV-1 Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate \[Oncovin\], cyclophosphamide, and doxorubicin hydrochloride \[hydroxydaunorubicin hydrochloride\], or "EPOCH") in treating adult T-cell leukemia-lymphoma. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma. Drugs used in chemotherapy, such as etoposide, vincristine, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving lenalidomide and the usual combination chemotherapy may work better in treating adult T-cell leukemia-lymphoma compared to the usual combination chemotherapy alone.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Lee Ratner
Yale University Cancer Center LAO
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Emory University Hospital Midtown
Atlanta, Georgia, United States
Pamela B. Allen
Recruiting
Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
Pamela B. Allen
Recruiting
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, United States
Lee Ratner
Recruiting
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, United States
Lee Ratner
Recruiting
Siteman Cancer Center-South County
St Louis, Missouri, United States
Lee Ratner
Recruiting
Washington University School of Medicine
St Louis, Missouri, United States
Lee Ratner
Recruiting
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States
Steven M. Horwitz →
Recruiting
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States
Steven M. Horwitz →
Recruiting
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States
Steven M. Horwitz →
Recruiting
Memorial Sloan Kettering Commack
Commack, New York, United States
Steven M. Horwitz →
Recruiting
Memorial Sloan Kettering Westchester
Harrison, New York, United States
Steven M. Horwitz →
Recruiting
Nyu Langone Hospital - Long Island
Mineola, New York, United States
Catherine S. Diefenbach
Recruiting
Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
Catherine S. Diefenbach
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Steven M. Horwitz →
Recruiting
Nyp/columbia University Medical Center/herbert Irving Comprehensive Cancer Center
New York, New York, United States
Jennifer E. Amengual
Recruiting
Nyp/weill Cornell Medical Center
New York, New York, United States
Jia Ruan
Recruiting
Memorial Sloan Kettering Nassau
Uniondale, New York, United States
Steven M. Horwitz →
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Jonathan E. Brammer
Recruiting
Vcu Massey Comprehensive Cancer Center
Richmond, Virginia, United States
Bruce O. Hough
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cyclophosphamide →Doxorubicin →Etoposide →Lenalidomide →Prednisone →Vincristine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2021
Primary completion: 30 Jun 2027
Completion: 30 Jun 2027
Last update posted: 16 Jul 2026
Registered enrollment: 30
Registry id: NCT04301076

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.